ST Jiaying released its 2026 interim report. Total operating revenue was 166 million yuan, down 16.68% year-on-year. Net profit attributable to the parent company was a loss of 12.98 million yuan, swinging from profit to loss year-on-year, a decline of 164.63%. Net cash flow from operating activities was a negative 54.80 million yuan, a decrease of 29.41 million yuan year-on-year. The company's asset-liability ratio was 16.80%, gross margin was 53.21%, return on equity was negative 1.84%, and diluted earnings per share was negative 0.03 yuan. The number of shareholders was 19,400, and the top ten shareholders held 35.07% of the total share capital.
Guangdong Jiaying Pharmaceutical Co LtdNet loss of 12.98 million yuan, swinging from profit to loss, with revenue down 16.68%.